LivaNova PLC (NASDAQ:LIVN) insider David S. Wise sold 1,500 shares of the stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $88.17, for a total value of $132,255.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:LIVN opened at $86.05 on Wednesday. LivaNova PLC has a 1 year low of $49.68 and a 1 year high of $92.31. The firm has a market capitalization of $4,131.74, a PE ratio of 24.24, a price-to-earnings-growth ratio of 2.67 and a beta of 0.75. The company has a quick ratio of 1.79, a current ratio of 2.14 and a debt-to-equity ratio of 0.03.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.10. LivaNova had a positive return on equity of 9.37% and a negative net margin of 2.10%. The company had revenue of $278.40 million during the quarter, compared to analysts’ expectations of $278.48 million. During the same quarter in the prior year, the business posted $0.83 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. sell-side analysts predict that LivaNova PLC will post 3.2 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. Cerebellum GP LLC bought a new position in LivaNova during the fourth quarter valued at about $128,000. QS Investors LLC boosted its stake in LivaNova by 27,255.6% during the fourth quarter. QS Investors LLC now owns 2,462 shares of the company’s stock valued at $197,000 after buying an additional 2,453 shares in the last quarter. Pillar Pacific Capital Management LLC bought a new position in LivaNova during the fourth quarter valued at about $208,000. Shelton Capital Management bought a new position in LivaNova during the third quarter valued at about $209,000. Finally, Affinity Investment Advisors LLC bought a new position in LivaNova during the fourth quarter valued at about $211,000. 85.51% of the stock is owned by institutional investors.
Several equities research analysts have weighed in on LIVN shares. ValuEngine lowered LivaNova from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. BidaskClub lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 12th. Zacks Investment Research lowered LivaNova from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 25th. Canaccord Genuity increased their target price on LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of LivaNova in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $81.43.
TRADEMARK VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/11/livanova-plc-livn-insider-david-s-wise-sells-1500-shares.html.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.